Abstract
The MIC(90) of RBx 14255, a novel ketolide, against Clostridium difficile was 4 μg/ml (MIC range, 0.125 to 8 μg/ml), and this drug was found to be more potent than comparator drugs. An in vitro time-kill kinetics study of RBx 14255 showed time-dependent bacterial killing for C. difficile. Furthermore, in the hamster model of C. difficile infection, RBx 14255 demonstrated greater efficacy than metronidazole and vancomycin, making it a promising candidate for C. difficile treatment.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / chemical synthesis
-
Anti-Bacterial Agents / pharmacology*
-
Clostridioides difficile / drug effects*
-
Clostridioides difficile / growth & development
-
Cricetinae
-
Drug Resistance, Bacterial / drug effects
-
Enterocolitis, Pseudomembranous / drug therapy*
-
Enterocolitis, Pseudomembranous / microbiology
-
Enterocolitis, Pseudomembranous / mortality
-
Humans
-
Ketolides / chemical synthesis
-
Ketolides / pharmacology*
-
Metronidazole / pharmacology
-
Microbial Sensitivity Tests
-
Survival Rate
-
Vancomycin / pharmacology
Substances
-
Anti-Bacterial Agents
-
Ketolides
-
Rbx 14255
-
Metronidazole
-
Vancomycin